Anca Bulgaru, MD
she/her/hers
Assistant Professor of Medicine (Medical Oncology)Cards
About
Research
Publications
2007
Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineered™ monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors
Goel S, Bauer R, Desai K, Bulgaru A, Iqbal T, Strachan B, Kim G, Kaubisch A, Vanhove G, Goldberg G, Mani S. Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineered™ monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors. Annals Of Oncology 2007, 18: 1704-1707. PMID: 17693421, DOI: 10.1093/annonc/mdm280.Peer-Reviewed Original ResearchConceptsING-1Human anti–human antibody (HAHA) responsesMonoclonal antibodiesGrade 3 pancreatitisAdvanced solid tumorsAdvanced refractory cancerPeak drug levelsRisk of pancreatitisAnti-tumor effectsStable diseaseMonotherapy studiesThird doseAntibody responseRefractory cancerMost adenocarcinomasDrug levelsPharmacokinetic samplesWeek 1Colon cancerPatientsSolid tumorsDrug accumulationCombination studiesFurther experienceSafety studiesPO-50 Management practices of Connecticut physicians for treatment of cancer patients with venous thrombosis
Dhami R, Bulgaru A, Jagathambal K, Johnson S, Kapur D, Slater D, Dhami M. PO-50 Management practices of Connecticut physicians for treatment of cancer patients with venous thrombosis. Thrombosis Research 2007, 120: s161. DOI: 10.1016/s0049-3848(07)70203-7.Peer-Reviewed Original Research
2006
Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers
Goel S, Desai K, Karri S, Gollamudi R, Chaudhary I, Bulgaru A, Kaubisch A, Goldberg G, Einstein M, Camacho F, Baker S, Mani S. Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers. Investigational New Drugs 2006, 25: 237-245. PMID: 17195945, DOI: 10.1007/s10637-006-9028-1.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsArea Under CurveCamptothecinCapecitabineCarboxylesteraseDeoxycytidineDose-Response Relationship, DrugDrug Administration ScheduleDrug InteractionsFemaleFluorouracilHumansInfusions, IntravenousIrinotecanMaleMiddle AgedNeoplasmsNeutropeniaTreatment OutcomeConceptsDrug-drug interactionsDay 1Day 8Open-label phase ISN-38Potential drug-drug interactionsConversion of irinotecanGrade 3 diarrheaCycles of chemotherapyAdvanced solid cancersAdvanced solid tumorsDose level 5Diarrhea/vomitingWarrants further evaluationSynergistic anti-cancer activitySN-38GWarrants further studyFatal neutropeniaOral capecitabineAnti-cancer activityDose cohortsEvaluable patientsEscalation trialNegative sepsisMin infusionTreatment of Acute Myeloid Leukemia in a Community Hospital.
Dhami M, Bulgaru A, Jagathambal K, Kapur D, Slater D, Maderazo E, Bauer F. Treatment of Acute Myeloid Leukemia in a Community Hospital. Blood 2006, 108: 4575. DOI: 10.1182/blood.v108.11.4575.4575.Peer-Reviewed Original ResearchAcute myeloid leukemiaTertiary care centerMyeloid leukemiaMedian survivalCare centerCommunity hospitalBone marrow/stem cell transplantSuch complex patientsSystemic chemotherapy regimenStem cell transplantNumber of patientsAcute care hospitalsBone marrow samplesSmall community hospitalBed acute care hospitalAPML patientsFAB subgroupsInduction therapyChemotherapy regimenClinical remissionRelapsed diseaseMost patientsCare hospitalMedian ageRetrospective review
2005
Use of Venipuncture Blood Sample for INR Testing on a Point of Care Machine.
Dhami M, Bulgaru A, Jagathambal K, Kapur D, Norris F, Slater D, Cavanaugh J. Use of Venipuncture Blood Sample for INR Testing on a Point of Care Machine. Blood 2005, 106: 4159. DOI: 10.1182/blood.v106.11.4159.4159.Peer-Reviewed Original ResearchInternational normalized ratioVenipuncture blood sampleINR testingPOC machineBlood samplesWarfarin therapyLong-term oral anticoagulationPOC INR testingSame dayFingerstick blood samplesProcedure of choiceSodium citrate tubesRegression analysisSame blood sampleAdditional laboratory testingOral anticoagulationINR monitoringDose modificationMost patientsAntecubital veinNormalized ratioBlood drawOncology practicePatientsVenipuncture samplesSingle Institution Experience with Inferior Vena Cava Filters.
Bhalla N, Bulgaru A, Church L, Kapur D, Lustberg H, Slater D, Dhami M. Single Institution Experience with Inferior Vena Cava Filters. Blood 2005, 106: 914. DOI: 10.1182/blood.v106.11.914.914.Peer-Reviewed Original ResearchDeep venous thrombosisRetrievable IVC filtersRecurrent deep venous thrombosisInferior vena cava filterSymptomatic pulmonary embolismPulmonary embolismPermanent IVC filtersIVC filtersVena cava filtersPermanent filtersClot burdenVenous thromboembolismCava filtersSymptomatic deep venous thrombosisTransient low-grade feverPoor pulmonary reserveRetrieval of filtersLow-grade feverRecurrent venous thromboembolismIncidence of complicationsIVC filter insertionLong-term anticoagulationSingle institution experienceAdverse clinical consequencesChest CT scanPhase I and pharmacokinetic study of a subcutaneously administered human-engineered monoclonal antibody ING-1 in patients with advanced adenocarcinomas
Kiner-Strachan B, Goel S, Vanhove G, Bauer R, Verdier-Pinard D, Karri S, Desai K, Bulgaru A, Macapinlac M, Mani S. Phase I and pharmacokinetic study of a subcutaneously administered human-engineered monoclonal antibody ING-1 in patients with advanced adenocarcinomas. Journal Of Clinical Oncology 2005, 23: 2558-2558. DOI: 10.1200/jco.2005.23.16_suppl.2558.Peer-Reviewed Original Research
2004
A phase I clinical trial with weekly irinotecan (IRI) and capecitabine (CAP) in patients with advanced gastrointestinal and other solid malignancies
Friedman D, Goel S, Desai K, Verdier-Pinard D, Kaubisch A, Bulgaru A, Camacho F, Goldberg G, Mani S. A phase I clinical trial with weekly irinotecan (IRI) and capecitabine (CAP) in patients with advanced gastrointestinal and other solid malignancies. Journal Of Clinical Oncology 2004, 22: 2113-2113. DOI: 10.1200/jco.2004.22.14_suppl.2113.Peer-Reviewed Original ResearchA phase I clinical trial with weekly irinotecan (IRI) and capecitabine (CAP) in patients with advanced gastrointestinal and other solid malignancies
Friedman D, Goel S, Desai K, Verdier-Pinard D, Kaubisch A, Bulgaru A, Camacho F, Goldberg G, Mani S. A phase I clinical trial with weekly irinotecan (IRI) and capecitabine (CAP) in patients with advanced gastrointestinal and other solid malignancies. Journal Of Clinical Oncology 2004, 22: 2113-2113. DOI: 10.1200/jco.2004.22.90140.2113.Peer-Reviewed Original Research
2003
Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors
Goel S, Bulgaru A, Hochster H, Wadler S, Zamboni W, Egorin M, Ivy P, Leibes L, Muggia F, Lockwood G, Harvey E, Renshaw G, Mani S. Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors. Annals Of Oncology 2003, 14: 1682-1687. PMID: 14581279, DOI: 10.1093/annonc/mdg453.Peer-Reviewed Original ResearchConceptsDose-limiting toxicityAdvanced solid tumorsSolid tumorsCycle 1Day 1Cycle 1 dose-limiting toxicitiesDose levelsPhase I clinical studyGrade 3 toxicityPhase II doseGemcitabine combinationNovel regimenPartial responseClinical studiesPatientsGemcitabineOxaliplatinRPTDTitration schemeTumorsDL-4RegimenCycle 2Further investigationDose
Clinical Care
Overview
Anca Bulgaru, MD, specializes in medical oncology and hematology with a focus on breast cancer care. She sees patients at the Smilow Cancer Hospital Cancer Care Center.
Dr. Bulgaru has a particular interest in high-risk management and genetic risk assessment for breast cancer, as well as addressing survivorship issues. She works to ensure her patients receive comprehensive care tailored to their individual needs, encompassing both treatment and long-term wellness.
In addition to her clinical practice, Dr. Bulgaru is an assistant professor of medicine at Yale School of Medicine. She received her medical degree from Carol Davila University of Medicine in Romania and completed her residency in internal medicine at St. Luke's Roosevelt Hospital in New York. She furthered her training with a fellowship at Montefiore Medical Center.
News
News
- October 29, 2024
Smilow Shares Breast Cancer Awareness: Empowered through Knowledge, Smilow at Waterford/Westerly
- October 16, 2024Source: WTNH
Smilow doctors use personalized medicine to treat breast cancer
- October 26, 2022Source: WTNH
Connecticut Woman Says Her Breast Cancer Didn’t Feel Like She Thought It Would
- June 09, 2022
Smilow Shares Survivorship Series: Young Adult Cancer Survivors
Get In Touch
Contacts
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.